94 Participants Needed

Ramucirumab + Chemotherapy for Small Bowel Cancer

Recruiting at 451 trial locations
CK
DS
Overseen ByDana Sparks
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Southwest Oncology Group
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This phase II trial studies how well ramucirumab and paclitaxel or the FOLFIRI regimen (leucovorin calcium, fluorouracil, and irinotecan hydrochloride) work in treating patients with small bowel cancers that have spread extensively to other anatomic sites (advanced) or are no longer responding to treatment (refractory). Ramucirumab is a monoclonal antibody that attaches to and inhibits a molecule called VEGFR-2. This may restrain new blood vessel formation therefore reducing nutrient supply to tumor which may interfere with tumor cell growth and expansion. Drugs used in chemotherapy, such as paclitaxel, leucovorin calcium, fluorouracil, and irinotecan hydrochloride work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving Ramucirumab plus paclitaxel or FOLFIRI, may be helpful in treating advanced or refractory small bowel cancers and may help patients live longer.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but you cannot be on chronic antiplatelet therapy like dipyridamole or clopidogrel. You also need to have completed any prior chemotherapy, immunotherapy, or radiation therapy at least 14 days before joining the trial.

Is the combination of Ramucirumab and chemotherapy safe for humans?

The combination of chemotherapy drugs like fluorouracil, leucovorin, and irinotecan has been studied for safety in various cancers, showing that they can cause side effects such as diarrhea, myelosuppression (reduced bone marrow activity), and neurotoxicity (nerve damage). However, supportive measures and dose adjustments can help manage these side effects. Ramucirumab, when combined with chemotherapy, has been used in other cancers, but specific safety data for small bowel cancer is not detailed in the provided research.12345

What makes the drug combination of Ramucirumab and chemotherapy unique for small bowel cancer?

This treatment is unique because it combines ramucirumab, a drug that targets blood vessel growth in tumors, with a chemotherapy regimen that includes drugs like fluorouracil and irinotecan, which are typically used for colorectal cancer. This combination may offer a novel approach for small bowel cancer, a condition with limited standard treatment options.678910

What data supports the effectiveness of the drug combination Ramucirumab + Chemotherapy for Small Bowel Cancer?

Research shows that chemotherapy, including drugs like 5-fluorouracil (5-FU) and irinotecan, can help prolong survival in patients with small bowel adenocarcinoma. Additionally, studies on similar drug combinations for colorectal cancer have shown positive responses, suggesting potential benefits for small bowel cancer as well.610111213

Who Is on the Research Team?

MJ

Michael J Overman

Principal Investigator

SWOG Cancer Research Network

Are You a Good Fit for This Trial?

This trial is for patients with advanced or refractory small bowel adenocarcinoma, excluding ampullary types. Participants must have previously progressed on fluoropyrimidine and/or oxaliplatin treatments, be at least 30 days stable post-brain metastases treatment if applicable, and not have had recent major surgery. They should not be pregnant/nursing, must agree to use contraception if of reproductive potential, and cannot have certain conditions like uncontrolled hypertension or a history of significant thromboembolism.

Inclusion Criteria

I have another cancer type, but it won't affect this trial's treatment.
I can carry out all my usual activities without help.
My liver function tests are within the required range.
See 14 more

Exclusion Criteria

Patients must not be currently enrolled in or have discontinued within the last 28 days a clinical trial involving an investigational product or non-approved use of a drug, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study. Patients participating in surveys or observational studies are eligible to participate in this study
My liver functions well, without severe disease or complications like serious fluid buildup.
I have not had a heart attack or stroke in the last 4 months.
See 12 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either ramucirumab and paclitaxel or FOLFIRI regimen. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

28 days per cycle
Multiple visits per cycle for IV administration

Follow-up

Participants are monitored every 8 weeks until disease progression, then every 6 months for up to 3 years post registration.

Up to 3 years
Every 8 weeks, then every 6 months

What Are the Treatments Tested in This Trial?

Interventions

  • Fluorouracil
  • Irinotecan
  • Irinotecan Hydrochloride
  • Leucovorin
  • Leucovorin Calcium
  • Paclitaxel
  • Ramucirumab
Trial Overview The study compares the effectiveness of Ramucirumab combined with Paclitaxel versus the FOLFIRI regimen (Fluorouracil, Leucovorin Calcium, Irinotecan Hydrochloride) in treating advanced small bowel cancers. Ramucirumab is an antibody that may inhibit tumor growth by blocking blood vessel formation while other drugs aim to kill or stop cancer cells from dividing.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Group I: Arm II (irinotecan, leucovorin, fluorouracil)Experimental Treatment5 Interventions
Patients receive irinotecan IV over 90 minutes on days 1 and 15, leucovorin IV over 2 hours on days 1 and 15, and fluorouracil IV bolus on days 1 and 15. Patients also receive fluorouracil IV over 46-48 hours on days 1-3 and 15-17. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Group II: Arm I (ramucirumab, paclitaxel)Experimental Treatment2 Interventions
Patients receive ramucirumab IV over 30-60 minutes on days 1 and 15, and paclitaxel IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Fluorouracil is already approved in United States, European Union, Canada for the following indications:

🇺🇸
Approved in United States as 5-Fluorouracil for:
  • Colorectal cancer
  • Breast cancer
  • Stomach cancer
  • Pancreatic cancer
  • Skin cancer
🇪🇺
Approved in European Union as 5-Fluorouracil for:
  • Colorectal cancer
  • Breast cancer
  • Stomach cancer
  • Pancreatic cancer
🇨🇦
Approved in Canada as 5-Fluorouracil for:
  • Colorectal cancer
  • Breast cancer
  • Stomach cancer
  • Pancreatic cancer

Find a Clinic Near You

Who Is Running the Clinical Trial?

Southwest Oncology Group

Lead Sponsor

Trials
389
Recruited
260,000+

SWOG Cancer Research Network

Lead Sponsor

Trials
403
Recruited
267,000+

National Cancer Institute (NCI)

Collaborator

Trials
14,080
Recruited
41,180,000+

Published Research Related to This Trial

In a study of 20 patients with advanced small bowel adenocarcinoma, chemotherapy combining 5-fluorouracil (5-FU) with platinum compounds showed a 21% overall response rate, with median progression-free survival of 8 months and overall survival of 14 months, indicating moderate efficacy and tolerability.
The combination of 5-FU and irinotecan demonstrated promising results, with 50% of patients achieving disease stabilization and one patient experiencing a complete biological response, suggesting that this combination warrants further investigation as a first-line treatment option.
Combination chemotherapy in advanced small bowel adenocarcinoma.Locher, C., Malka, D., Boige, V., et al.[2022]
In a phase II study involving 24 patients with metastatic or recurrent small bowel adenocarcinoma, the mFOLFOX6 chemotherapy regimen demonstrated a 1-year progression-free survival (PFS) rate of 23.3%, indicating some efficacy as a first-line treatment.
The treatment was generally well tolerated, with no treatment-related deaths reported, although significant side effects included neutropenia (38%) and anemia/peripheral neuropathy (25%).
A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma.Horimatsu, T., Nakayama, N., Moriwaki, T., et al.[2022]
In a study of 74 patients with metastatic colorectal cancer (mCRC) receiving second-line treatment with FOLFIRI plus ramucirumab, the median progression-free survival (PFS) was 6.2 months and median overall survival (OS) was 17.0 months, indicating a significant therapeutic benefit.
Patients who had not previously received bevacizumab (bevacizumab-naïve) showed better treatment responses, with a response rate of 23% and a disease control rate of 85%, compared to only 3% and 69% in those who had received bevacizumab as first-line therapy.
Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer.Suzuki, T., Shinozaki, E., Osumi, H., et al.[2023]

Citations

Combination chemotherapy in advanced small bowel adenocarcinoma. [2022]
A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma. [2022]
Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer. [2023]
European experience with irinotecan plus fluorouracil/folinic acid or mitomycin. [2018]
Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer--a phase II study. [2019]
6.Czech Republicpubmed.ncbi.nlm.nih.gov
High vs. low-dose leucovorin in regimens with fluorouracil in colorectal cancer therapy. [2023]
First clinical experience with the magnetic resonance imaging contrast agent and superoxide dismutase mimetic mangafodipir as an adjunct in cancer chemotherapy-a translational study. [2021]
Does radiation prevent 5-fluorouracil-induced colitis in the early phase of radiochemotherapy? A case report and literature review. [2013]
S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies. [2018]
Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer. [2018]
Risk Benefit of FOLFIRI Plus Ramucirumab as Third-line and Later-line Treatment of Metastatic Colorectal Cancer. [2023]
Placental growth factor is a predictive biomarker for ramucirumab treatment in advanced gastric cancer. [2023]
The safety and efficacy of ramucirumab for the treatment of metastatic colorectal cancer. [2023]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security